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Effects of In Vitro Purging With 4-Hydroperoxycyclophosphamide
on the Hematopoietic and Microenvironmental Elements
of Human Bone Marrow
By Salvatore Siena, Hugo Castro’-Malaspina, Subhash C. Gulati, Li Lu, Michael 0. Colvin, Bayard D. Clarkson,
Richard J. O’Reilly, and Malcolm A.S. Moore
We describe the effects of 4-hydroperoxycyclophospha-
mide (4-HC) on the hematopoietic and stromal elements of
human bone marrow. Marrow cells were exposed to 4-HC
and then assayed for mixed (CFU-Mix). erythroid (BFU-E).
granulomonocytic (CFU-GM). and marrow fibroblast (CFU-
F) colony-forming cells and studied in the long-term mar-
row culture (LTMC) system. The inhibition of colony forma-
tion by 4-HC was dose and cell-concentration dependent.
The cell most sensitive to 4-HC was CFU-Mix (lD 31
smol/L) followed by BFU-E (lD, 41 smol/L). CFU-GM (lD
89 moI/L). and CFU-F (lD 235 imol/L). In LTMC. a
dose-related inhibition of CFU-GM production was noted.
Marrows treated with 300 tmol/L 4-HC were completely
depleted of CFU-GM but were able to generate these
progenitors in LTMC. Marrow stromal progenitors giving
rise to stromal layers in LTMC. although less sensitive to
4-HC cytotoxicity. were damaged by 4-HC also in a dose-
related manner. Marrows treated with 4-HC up to 300
4 - H YDROPEROXYCYCLOPHOSPHA M IDE
(4-I-IC) is a derivative of cyclophosphamide that
exhibits in vitro chemical and biologic properties simi-
lam to those of microsomally activated cyclophospha-
mide.”2 In 1980, Shankis et al3 showed that 4-HC can
selectively purge munine acute leukemia cells from
marrow suspensions in a dose-related manner without
affecting the viability and self-renewal capacity of the
nonleukemic plunipotential hematopoietic stem cells
(CFU-s). These studies provided the rationale for the
application of 4-HC purged autologous bone marrow
transplantation to the treatment of human leukemia4
and lymphoma.5 Thus autologous bone marrow ham-
vested in remission, which has high risk of being
contaminated with microscopically undetectable ma-
lignant cells, can be purged in vitro with 4-HC and
then neinfused to reverse the lethal aplasia induced by
preceding ablative chemoradiothemapy.4’5
The successful engnaftment of transplanted bone
marrow requires, besides intact primitive hemato-
poietic stem cells, a functional microenvironment on
stroma in which hematopoietic stem cells can self-
replicate and differentiate.6’7 In humans, the marrow
stromal cell (MSC) population comprises fibroblasts,
endothelial cells, adipocytes, and macrophages.8’#{176}
Recent studies have shown that the stromal cells
forming the in vitro microenvironment in human Dex-
ten-type long-term marrow culture (LTMC) generated
from marrow aspirates of allogeneic marrow trans-
plant recipients are of donor origin and that the
smol/L. gave rise to stromal layers composed of fibro-
blasts. endothelial cells. adipocytes. and macrophages.
Cocultivation experiments with freshly isolated autologous
hematopoietic cells showed that stromal layers derived
from 4-HC-treated marrows were capable of sustaining
the long-term production of CFU-GM as well as controls. In
conclusion: (1 ) Hematopoietic progenitors cells. CFU-Mix.
BFU-E. and CFU-GM. are highly sensitive to 4-HC. whereas
marrow stromal progenitor cells are relatively resistant. (2)
Marrows treated with 300 mol/L 4-HC that are depleted
of CFU-Mix. BFU-E. and CFU-GM can generate CFU-GM in
LTMC. suggesting that most primitive hematopoietic stem
cells (not represented by CFU-Mix) are spared by 4-HC up
to this dose. (3) Consequently. the above colony assays are
not suitable tools for predicting pluripotent stem cell
survival after 4-HC treatment in vitro.
 1985 by Grune & Stratton. Inc.
percentage of donor cells contributing to the culture
stromal microenvi non ment progressively i ncneases in
marrow aspirates taken at greaten times after trans-
plantation.” Although no evidence has been provided
that the proliferation of donor MSCs in vivo is neces-
sary to support grafted hematopoietic cells, it is con-
ceivable that transplantation of MSCs constitutes a
factor of critical functional 12
The studies presented here were aimed at evaluating
the effects of 4-HC on the hematopoietic stem cells
and stromal elements of human bone marrow. Evi-
dence is presented demonstrating that multipotential
(CFU-Mix) and enythmoid (BFU-E) colony-forming
cells are highly sensitive to the cytotoxic effect of
4-HC. In contrast, MSCs are relatively resistant and
not functionally affected by the doses of 4-HC cur-
mently used for purging autologous bone marrow.
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MATERIALS AND METHODS
Bone Marrow Cells
Bone marrow cells were obtained by aspiration from the iliac crest
of healthy volunteers who gave informed written consent. Preserva-
tion-free heparin was used as anti-coagulant (Weddel Pharmaceuti-
cals ltd. london). Buffy coats were collected after centrifugation of
the aspirates at 200 g for ten minutes. Cells were washed and
resuspended in alpha modification of Eagle’s medium (Flow Labora-
tories, Hamden, Conn) supplemented with 10% fetal calf serum
([FCSI Sterile Systems, logan, Utah).
4-Hydroperoxycyclophosphamide and Incubation
Procedure
The 4-HC (mol wt 292) used in the present experiments was
prepared by Dr Michael 0. Colvin (from the Johns Hopkins
Oncology Center, Baltimore). The synthesis and purification proce-
dures have been described elsewhere.’ The 4-HC powder was
dissolved in calcium- and magnesium-free phosphate-buffered solu-
tion (PBS), then sterilized by filtration, and used within 30
minutes.
Marrow buffy coat cells at a final concentration of 10 or 20 x 106
cells per milliliter were incubated at 37 #{176}Cfor 30 minutes with 25 to
500 pmol/l 4-HC and medium control. The cell suspensions were
then washed at 10 #{176}Cand assayed for colony-forming cells or
inoculated for long-term culture according to the experimental
design. The incubation procedure was similar to the one used for
clinical trials of 4-HC-purged autologous marrow transplantation.
Ten percent FCS was constantly included in all marrow suspensions.
Viability was not significantly changed by the incubation proce-
dure.
Colony Assays
Mixed and erythroid colony-forming cells. The assay for CFU-
Mix was carried out according to the method of Fauser and
Messner’3 as described previously.’4 Control and 4-HC-treated bone
marrow cells were plated at 2 x iO in 35-mm tissue culture dishes
(Lux Scientific Co. Newburg, Calif) containing a 1-mL mixture of
Iscove’s modified Dulbecco medium, 1% methyl-cellulose, 30% FCS,
5% medium conditioned by leukocytes in the presence of 1%
phytohemagglutinin (HA-IS, Wellcome Reagents ltd. Wellcome
Research laboratories, Detroit) and 5 x lO mol/l 2-mercapto-
ethanol and I unit of a step III preparation of sheep plasma
erythropoietin (Connaught Laboratories ltd. Willowdale, Ontario,
Canada). Dishes were incubated at 37 #{176}Cin a humidified atmo-
sphere flushed with 5% CO2 in air. CFU-Mix were scored with an
inverted microscope after I 4 days of incubation and were identified
further by plucking out colonies with a fine pipette and staining with
benzidine and/or Wright-Giemsa stain. CFU-Mix usually contained
erythroid, granulocyte, monocytic, and megakaryocytic cells. BFU-
E were scored from the same plates.
Granulocyte-macrophage colony-forming cells. Colony (more
than 50 cells per aggregate) and cluster (three to 50 cells per
aggregate) formation of control and 4-HC.-treated bone marrow
cells were stimulated by 10% exogenously supplied granulocyte-
macrophage colony-stimulatory factors present in medium condi-
tioned by the human monocytic cell line GCT (GIBCO Laborato-
net, Grand Island, NY). Control and 4-HC-treated cells were
plated at 2 x l0 in I ml ofO.3% agar culture medium (Difco labs,
Detroit) that included McCoy’s 5A medium supplemented with
essential and nonessential amino acids, glutamine, serine, aspara-
gine, sodium pyruvate (GIBCO) as well as 10% heat-inactivated
fetal bovine serum. Cultures were incubated at 37 #{176}Cin a humidified
atmosphere of 5% CO2 in air and scored for colonies and clusters
after seven days of incubation.
Fibroblast colony-forming cells. The general procedure has
been described previously.’5’6 Briefly, control and 4-HC-treated
marrow cells resuspended in alpha-medium supplemented with 20%
FCS, penicillin (100 U/mI), and streptomycin (100 Mg/mI) were
cultured in T-75 tissue culture flasks (Corning Glass Works, Corn-
ing, NY). Five x lO6cells were incubated per flask; three flasks were
used per point. The flasks were gassed with 5% CO2 in air and
incubated at 37 #{176}C.The culture medium was totally renewed on day
4. After ten days of incubation, the cultures were stopped. For
scoring fibroblast colonies, the flasks were stained with Wright-
Giemsa stain and examined with an inverted microscope at 25x.
Fibroblastoid cell aggregates of more than 50 cells were scored as
CFU-F. The fibroblastic nature of cells composing the colonies was
demonstrated by immunofluorescence staining with antibodies
against fibronectin and types I and Ill collagen as described
previously. ‘ 5.16
Long-term Marrow Cultures
ITMCs were established according to the method of Moore et
al’7’0 as modified by Gartner and Kaplan.’9 Twenty to forty x 106
control and 100, 300, and 400 mol/l 4-HC-treated marrow buffy
coat cells in 10 ml of ITMC medium were inoculated into T-25
tissue culture flasks. The cultures were then gassed with 5% CO2 in
air and incubated at 33 #{176}C.The LTMC medium consisted of
McCoy’s 5A medium supplemented with 1% minimal essential
medium (MEM) sodium pyruvate solution, 0.8% MEM essential
amino acids solution, 0.4% MEM nonessential amino acids solution,
1% MEM vitamins solution, 1% penicillin-streptomycin solution, 1%
glutamine-asparagine-serine solution, 12.5% horse serum, I 2.5%
FCS, and l06 mol/l hydrocortisone sodium succinate. On day 3 of
incubation, in order to eliminate the contaminating erythrocytes and
mature myeloid cells, the nonadherent cells were gently aspirated
out of the flasks and enriched for mononuclear cells by neutral
density centrifugation in an isotonic sterile Percoll solution (1.074
g/ml, 270 mosm) (Pharmacia Fine Chemicals, Piscataway, NJ) as
described previously2#{176} The resulting buoyant, mononuclear cell-
enriched fraction was collected, washed twice, resuspended in 5 mL
of LTMC medium, and reinoculated into the original flasks contain-
ing the adherent stromal layers and fresh LTMC medium. The latter
was added (5 ml per flask) soon after the nonadherent cells were
aspirated out of the flasks. At weekly intervals, half the supernatant
medium and suspension cells were removed and replaced with fresh
ITMC medium. Cells in suspension were counted, checked for
viability by trypan blue dye exclusion test, and assayed for CFU-
GM. Individual ITMCs were examined every seven days under a
phase contrast inverted microscope, and the percentage of the flask
surface covered by a stromal interlocking network was semiquantita-
lively assessed. Grades I through 4 corresponded to 25% to I 00% of
the base of each flask that was covered by a stromal network. At the
time of stopping the culture (week 6 to 7), the CFU-GM content of
the adherent layers derived from control and 4-HC-treated marrows
was assessed using the following procedure. Individual flasks were
gently washed twice to remove remaining nonadherent cells, and 2
ml ofa 0.01% (wt/vol) Ca -Mg 4-free trypsin (GIBCO) solution
was added to the flask and it was incubated at 4 #{176}Cfor 15 to 20
minutes. The cells that had been detached by the trypsin treatment
(80% to 90% of the adherent fraction) were aspirated out from the
flask, diluted I :1 with McCoy’s medium containing 10% FCS,
counted, and assayed for CFU-GM as the nonadherent cell fraction.
In independent experiments using fresh marrow buffy coat cells, this
trypsin treatment inhibited the CFU-GM growth by less than 5%.
To assess the capacity of the stromal layers established from 100
 only.
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zmol/l 4-HC-treated marrows to sustain hematopoiesis in vitro,
five-week-old primary ITMCs were totally depleted of all suspen-
sion cells, and a second inoculum of autologous bone marrow was
added. This consisted of 20 x 106 light-density (<1.074 g/ml)
Percoll-separated nonadherent autologous marrow cells. Percoll-
separated cells were allowed to adhere to the bottom of T-75 tissue
culture flasks at 37 #{176}Ctwice, for one hour each time. After adher-
ence, the nonadherent light-density (NAI) autologous cells were
extensively washed and added as dispersed single-cell suspension in
fresh LTMC medium. The experimental groups included (a) NAI
cells on stromal layers from 4-HC-treated marrow, (b) cell-free
LTMC medium on stromal layers from 4-HC-treated marrow, (c)
NAL cells in LTMC medium without any stromal layer, (d) NAL
cells on control stromal layers, and (e) cell-free ITMC medium on
control stromal layers. Cultures were demipopulated weekly and fed
with the same amount of fresh LTMC medium. The total cell counts
and CFU-GM numbers per flask were determined weekly.
Immunocytochemical Analysis ofthe Adherent
Layer of LTMCs
The heterogeneity of the cells constituting the adherent layer of
LTMCs established with 4-HC-treated marrow was assessed by
immunofluorescence (IMF) methods using specific antibodies
directed against components known to be associated with fibroblasts,
endothelial cells, and macrophages as described previously.’5’62’
These studies were performed in situ after the removal of the upper
portion of culture flasks with a heated scalpel and double washing
with PBS, pH 7.4.
Fibroblasts were identified by rabbit antibodies to type III
collagen (kindly provided by Dr S. Gay from the University of
Alabama) and human fibronectin (Bethesda Research laboratories,
Gaithersburg, Md). Endothelial cells were identified by rabbit
antiserum to human factor VIll-related protein (Calbiochem-
Behring, San Diego). Macrophages were identified by mouse mono-
clonal antibodies to human monocytes (Bethesda Research Labs).
Furthermore, the distribution of lipid-containing cells was studied
using the oil red 0 staining for neutral fat as elsewhere described.22
RESULTS
Effect of4-Hydroperoxycyclophosphamide on
Multipotential, Erythroid, and
Granulocyte-Macrophage Colony-Forming Cells
The percentage of recovery of CFU-Mix, BFU-E,
and CFU-GM in comparison to that of CFU-F is
depicted in Fig I . Treatment of marrow buffy coat
cells at 20 x 106 cells pen milliliter with 100 tmol/L
4-HC resulted in 100% ± 0%, 97% ± 1%, 71% ± 6%,
and 17% ± 7% inhibition ofCFU-Mix, BFU-E, CFU-
GM, and CFU-F formation, respectively. Treatment
with doses higher than those indicated in Fig 1 , ie, 150,
cFu-F CFU-MIX 8FUE OU.4
I’iITj L”’’,\J
02550 00 02550 00 02550 00 02550 00
4-HYoRoPERoxYcvcwPHosPHau,or ltM I
Fig 1 . Comparison of the effect of 4-HC on human marrow
stromal and hematopoietic progenitor cells. Marrow cells were
incubated with 4-HC. washed. and then assayed for fibroblast
(CFU-F). mixed (CFU-Mix). erythroid (BFU-E), and granulocyte-
macrophage (CFU-GM) colony-forming cells. Values shown are the
mean ± SEM from four (CFU-GM) and three (CFU-Mix. BFU-E)
separate experiments and are expressed as percentage of control
values. The control for CFU-Mix was 1 0.3 ± 0.9; BFU-E. 98 ± 26;
CFU-GM. 79 ± 23; CFU-F, 91 ± 1 1 . Note that CFU-F are relatively
resistant to 4-HC as compared with CFU-Mix. BFU-E. and CFU-
GM.
200, 300, and 500 j.mol/L 4-HC, resulted in 80% ±
2%, 96% ± 2%, 99.0% ± 0.5%, and 100% ± 0%
inhibition of CFU-GM growth. The ID50 of CFU-Mix,
BFU-E, and CFU-GM formation was 31, 41, and 89
mol/L 4-HC.
Treatment of marrow buffy coat cells at a lower cell
concentration, ie, 10 x 106 per milliliter, with 50, 100,
150, 200, 300, and 500 tmol/L 4-HC resulted in
59% ± 19%, 87% ± 5%, 96% ± 2%, 99.0% ± 0.5%,
100% ± 0%, and 100% ± 0% inhibition of CFU-GM
growth, respectively. The ID50 of CFU-GM formation
was 22 tmol/L 4-HC.
When 25 imol/L 4-HC-tmeated marrow cells were
mixed at different ratios with autologous untreated
marrow buffy coat cells and plated for CFU-GM,
BFU-E, and CFU-Mix, the observed number of cob-
nies closely corresponded to the expected values calcu-
bated on the basis ofdilution in the cell mixtures (Table
1).
Effect of4-Hydroperoxycyclophosphamide on
Marrow Fibroblast Colony-Forming Cells
The percentage of recovery of CFU-F after incuba-
tion with 50 to 500 zmol/L 4-HC is shown in Fig 2.
The pattern of recovery was clearly dose and cell-
concentration dependent. The dose of 4-HC inhibiting
50% (ID50) of the growth of CFU-F was 235 imol/L
Table 1 . Influence of Untreated Marrow Cells on C FU-GM. BFU-E. and CFU-Mix Growth From 4- HC-Treated Human Bone Marrow
CFU-GM per iO Cells
4-HC-Treated-Untreated
Ratio of Cultured Cells Observed Expected
BFU-E per 2 x 10’ Cells CFU-Mix per 5 x 10’ Cells
O/E Observed Expected O/E Observed Expected O/E
3:0 27.2 -
2:1 39.9 41.5
1:1 51.0 48.7
1:2 53.7 55.8
0:3 70.2 -
-
0.96
1.04
0.96
-
55 -
60 58.2
63 60.0
66 61.6
65 -
-
1.03
1.05
1.07
-
3.5 -
4.0 5.0
6.5 6.0
6.1 6.7
8.5 -
-
0.80
1.08
0.91
-
OlE. observed-expected ratio.
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Fig 3. Stromal development in long-term cultures of 4-HC-
treated human bone marrow. Marrow cells (20 x 10 per milliliter)
were incubated with 100 Mmol/L 4-HC. washed, and then inocu-
lated for long-term culture. At weekly intervals. the stromal layer
from experimental groups was graded by phase microscopy as
described in Materials and Methods. Results are from four sepa-
rate experiments. and each point represents the median score of
triplicates. A heterogeneous stromal layer can be established after
treatment with 4-HC. although a double number of 4-HC-treated
cells is required to obtain a stromal layer similar to controls. 0.
Control: 20 x 10’ cells/flask; Li. 4-HC treated: 20 x 10’ cells!
flask; A. 4-HC treated: 40 x 10’ cells/flask.
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Cvrg, percentage of coverage of culture flask surface; F, fibroblast; EC, endothelial cell; A, adipocyte; M, macrophage; ND, not determined; - , 0%;
+, <10%; + +. 10% to25%; + + +. 26% to75%; + + + +, >75%.
ediu,n 50 00 ISO 200 300 500
4 HYDR0PER05YCL0PH0SPHAMIDE (1iMl
Fig 2. Effect of 4-HC on human marrow fibroblast colony-
forming cells. Marrow cells were incubated with 4-HC. washed.
and then assayed for CFU-F. Values shown are the mean ± SEM
from five separate experiments and are expressed as percentage
of control values. The control CFU-F was 91 ± 1 1 . Note that the
toxic effect of 4-HC is dose and cell-concentration dependent.
when the cells were treated at a final concentration of
20 x 106 cells pen milliliter. The ID50 was I I 5 ,mol/L
when the incubation with 4-HC was carried out at
I 0 x I 6 cells pen milliliter. Thus treatment at a higher
cell concentration resulted in a lower cytotoxic effect
of4-HC on CFU-F.
Establishment of LTM(s With
4-Hydroperoxycyclophosphamide-Treated Bone
Marrow
Human bone mammows treated with 100 and 300
tmol/L 4-HC and then cultured in LTMC were
ultimately capable of giving rise to an adherent stro-
mal layer. In contrast, treatment of the same mamnows
with 400 smol/L 4-HC impaired their capacity to
establish an LTMC. Figure 3 shows the stromal devel-
opment in cultures of control and 100 tmol/L
4-HC-tmeated marrow as a percentage of the surface
of the culture flask covered by the stromal network. At
initial stages of culture, weeks 1 to 3, the extent of the
stromal layer derived from untreated marrow was
more extensive. However, in the following weeks, when
confluence was already reached in the untreated
group, the 4-HC-treated stromal layers became pro-
gnessively confluent and comparable to controls. In-
oculation of a higher number of treated marrow cells
(40 x 106 pen flask) resulted in the formation of
stromal layers equivalent in extent to those formed by
20 x 106 untreated marrow cells.
The analysis of the distribution and identify of the
cells composing the stromal layer of five-week-old
LTMCs established with 4-NC-treated mammows is
shown in Table 2. In LTMCs derived from 100 and
300 zmol/L 4-HC-treated mannows, fibroblasts con-
stituted the predominant (>75%) adherent cell popu-
lation. Endothelial cells were found sparsely (<10%)
distributed within these stromal layers, except in one
experiment among the 300 tmol/L 4-HC-tmeated
group. Groups of lipid-containing cells were present in
all cultures. Ten percent to 25% (three experiments)
and 40% (one experiment) macnophages could be
identified in the stmomal layers derived from 100
smol/L 4-HC-treated mamrows. Less than 10% (two
experiments) and 10% to 25% (one experiment)
macrophages were found in the stnomal layers derived
from 300 tmol/L 4-HC-tmeated manrows. In contrast,
the in vitro stroma derived from 400 tmol/L
Table 2. Extent and Composition of the Stromal Layers of Five-Week-Old Long-Term Cultures
Derived From 4-HC-Treated Human Bone Marrow
Experiment
No.
4-HC 100 Mmol/L 4-HC 3 00 moI/L 4-HC 400 zmol/L
Cvrg F EC A M Cvrg F EC A M Cvrg F EC A M
1 100 ++++ + ++ ++ 75 ++++ + ++ ++ <10 ± ND - -
2 100 +++ + ++ +++ 75 ++++ - ++ + <10 ± - - -
3 75 ++++ + ++ ++ 100 ++++ + ++ + <10 - ND - -
4 100 ++++ + ++ ++
A heterogeneous stromal layer derived from 20 x 106 untreated buffy-coat cells exhibits the following composition: fibroblasts, 3  to 4  ; endothelial
cells, ± to 1  ; adipocytes, 2 ‘ to 3  ; macrophages 2  to 3  . All cultures were initiated with 40 x 1 0e 4-HC-treated marrow buffy coat cells per
flask.
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Fig 4. Sustained production of granulocyte-macrophage cob-
ny-forming cells on heterogeneous stromal layers derived from
4-HC-treated marrow. After depopulation of all suspension cells.
20 x 1 0’ autobogous NAL marrow cells were added to five-
week-old stromal layers of long-term cultures initiated with 40 x
1 0’ 4-HC-treated cells per flask. Cultures were demipopulated
weekly. and the total cell counts and CFU-GM numbers per flask
were determined. Each datum point represents the cumulative
number of mean CFU-GM recovered from the cultures (two to
three culture flasks per group). No correction was made for the
depopulations owing to the weekly replacement of half the LTMC
medium volume. In this representative experiment, the NAL cell
inoculum containing 9.3 x 1 O CFU-GM was added to 4-HC-
pretreated stromal layers (#{149}).non-pretreated stromal layers (a).
and controls with no stromal layers ( 0 ). Heterogeneous stromal
layers derived from 4-HC-treated marrow could sustain the long-
term production of CFU-GM in a manner similar to controls. No
CFU-GM growth was observed in additional controls with no
added cells: layers from 4-HC-treated marrow and layers from
non-pretreated marrow (data not shown in this figure).
IN VITRO EFFECTS OF 4-HC ON HUMAN MARROW 659
4-HC-treated mannows consisted only of a few scat-
tered spots of fibmoblasts (Table 2).
To assess the functional capacity of stnomal layers
established from 4-HC-treated marrow to sustain
hematopoiesis in vitro, primary LTMCs were totally
depleted of all suspension cells after five weeks, when
the total CFU-GM produced pen culture was reduced
to 45 ± 2 1 . Five groups of cultures were then initiated
using a second addition of autologous NAL marrow
cells (see Materials and Methods). As shown in Fig 4,
no impairment in the production ofCFU-GM was seen
in the group involving the cocultume of NAL cells with
stromal layers from 4-HC-tneated marrow as com-
pared with stnomal layers derived from untreated
marrow. In flasks inoculated with NAL cells without
any stromal support, the production of CFU-GM was
remarkably lower and of short duration (Fig 4). In no
instance were CFU-GM found in the nonadhenent
fraction of the flasks depopulated of all buoyant cells
and not neinoculated with fresh NAL cells (not shown
in Fig 4). This finding ruled out the possibility that
control number of CFU-GM were released from the
adherent layers derived from 4-HC-tneated marrow.
The numbers of total CFU-GM and nonadhenent
cells in primary long-term cultures derived from con-
trol and 4-HC-treated mamnows are summarized in
Table 3. In comparison to control cultures, in the first
two weeks the decline of the total nonadherent cell
number was slower in the 100 and 300 j.tmol/L
4-HC-tneated groups. Despite weekly demipopulation
of the cultures, continuous production of CFU-GM
could be detected in the nonadhenent fraction of the
100 tmol/L 4-HC-tneated group for five weeks. In the
300 j.zmol/L 4-HC-tmeated group, although the pni-
many inoculum was virtually depleted ofall CFU-GM
(0. 16 ± 0.20 per culture), a modest generation of these
committed stem cells was found on week 1 and week 2
of culture. Treatment with 400 jsmol/L 4-HC abol-
ished CFU-GM growth in LTMCs. On weeks 6 to 7 of
culture, CFU-GM were occasionally found in the
adherent fraction of control LTMC, whereas in no
instance could CFU-GM be detected in the LTMC
derived from 4-HC-treated mannows.
DISCUSSION
Data presented in this paper show that the 4-HC
doses currently used for marrow purging in autologous
transplantation, although depleting the graft of hema-
topoietic progenitors, including the putative plunipo-
T able 3. Primary Long-term Cultures Dc rived From C ontrol and 4-HC- Treated Human Bone Marrow
Total Nonadherent Cells per Culture ( x 10’) Total CFU-GM per Culture
Week
.
Medium
Controlt
4-HC (MmoI/L) .
Medium
Controlt
4-HC
100 300 400 ioo 300 400
1
2
3
4
5
6
91 ± 29
34 ± 11
10 ± 7
6 ± 1
2 ± 1
0.6 ± 0.5
76 ± 19(41) 25 ± 20(14)
36 ± 23(52) 21 ± 13(31)
6.6 ± 1.5 (33) 1.5 ± 1.0 (7)
3.6 ± 3.0 (30) 0.8 ± 0.5 (7)
0.6 ± 0.5 (15) 0
0 0
17 ± 10
1.3 ± 1.0
0.3 ± 0.1
0.3 ± 0.1
0
0
4,133 ± 275
1,828 ± 321
370 ± 21
159 ± 87
45 ± 21
3.3 ± 3.0
1,312 ± 387(16) 13 ± 7(<1)
364 ± 98(10) 1.1 ± 0.5(<1)
1 16 ± 36 (16) 0
38.3 ± 19.0 (12) 0
3.3 ± 3.0 (4) ND
0 ND
0
0
0
0
ND
ND
Mean ± SEM of four (100 moI/L 4-HC) and three (300 and 400 smoI/L 4-HC) separate experiments. All cultures were incubated at 33 #{176}Cand
subjected to removal of half the growth medium and nonadherent cells at weekly intervals. . primary inoculum 20 x 1 O’/per flask containing 9, 1 64 ±
497 CFU-GM; , primary inoculum 40 x 108/per flask containing 2,610 ± 301 (100 .tmol/L 4-HC group), 0.16 ± 0.20 (300 zmol/L group), and 0
(400 zmol/L group) CFU-GM; ( ). percentage of control cultures corrected for the number of initial inoCulum; ND, not determined.
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tent stem cells on CFU-Mix, do not significantly affect
the number and function of MSC. The dose of 4-HC
used in clinical marrow purging is limited by its
toxicity on hematopoietic stem cells. This has been
estimated indirectly by assaying the frequency of
CFU-GM in the harvested marnows before and after
4-HC treatment.23 Interestingly, clinical tnansplanta-
tion data have shown that despite CFU-GM depletion,
4-HC-purged autologous grafts retain their capacity
to reconstitute the hematopoietic system of transplant
patients pretreated with myeboablative chemonadio-
therapy.4’5 This lack of correlation between in vitro
CFU-GM recovery and in vivo manrow-nepopulating
ability suggests that (I) the measured CFU-GM does
not reflect the survival of primitive plunipotential stem
cells, or (2) the treatment with 4-HC causes the loss of
an accessory cell(s) necessary for the in vitro but not
for the in vivo growth of hematopoietic stem cells. To
address the first possibility, we studied the 4-HC
sensitivity of CFU-Mix, a progenitor cell with self-
renewal charactemistics2426 that has been considered
the putative primitive stem cell. Our results demon-
strate that CFU-Mix and BFU-E are even more
4-HC-sensitive than is CFU-GM. The possibility that
4-HC is toxic to an accessory cell(s) necessary for the
in vitro growth of hematopoietic stem cells was ruled
out by the results of mixing experiments (4-HC-
treated + untreated marrow cells at various ratios).
Therefore, the CFU-Mix assay also appears to be an
unsuitable tool for predicting the engraftment capabil-
ity of 4-HC-punged grafts. Moreover, the fact that I 00
and 300 tmol/L 4-HC-tneated bone marrow (ie,
depleted of CFU-Mix) can reinstitute full hemato-
poietic function in supralethally irradiated patients4’5
indicates that CFU-Mix does not represent the stem
cell responsible for hematopoietic reconstitution of the
transplanted host and suggests that theme are early
plunipotent stem cells that are significantly less
affected by 4-HC.
In an attempt to shed further light on the sensitivity
of early hematopoietic stem cells, we measured the
production of CFU-GM in primary LTMCs derived
from control and 4-HC-tneated marrow. Despite
weekly demipopulation of the cultures, CFU-GM
could be detected in the nonadhenent fraction up to
week 5 (100 .tmol/L 4-HC-treated group) and week 2
(300 mol/L 4-HC-treated group) of culture. In the
latter group, a low number ofCFU-GM was generated
despite almost complete CFU-GM depletion in the
initial inoculum. In contrast, 400 .tmol/L 4-HC-
treated mamrows failed in all instances to generate any
CFU-GM. These data suggest that the primitive pluni-
potent stem cells are affected by 4-HC also in a
dose-related manner but to a lessen degree than the
more differentiated hematopoietic stem cells, since
their capacity to proliferate and differentiate into
CFU-GM is spared by treatment with 4-HC up to 300
jsmol/L. Two lines of evidence support this notion.
First, previous studies by our group have shown that
the probable human plunipotent stem cells that are
detected in LTMC are Ia-antigen-negative,’8 whereas
human CFU-Mix are Ia-antigen-positive.’4 This dif-
fenence suggests that the two assays detect distinct
cells within a hierarchy of stem cell differentiation,
proliferation, and self-renewal capacity. Second, Bot-
nick et al2T in mice and Smith et al2t in humans have
shown that very-high-dose cyclophosphamide adminis-
tration in vivo results in rapid depletion of committed
hematopoietic stem cells and pancytopenia, which is
followed by prompt hematologic recovery. These find-
ings imply that cyclophosphamide on derivatives are
more sparing of the most primitive hematopoietic stem
cells.
Assessment of the effects of 4-HC on the MSC
compartment by the LTMC system and the CFU-F
assay showed that human MSCs are quantitatively but
not functionally affected by the in vitro procedures for
marrow purging with 4-HC. The unique adherent
stnomal layer found in the LTMC system is deemed
necessary for continuing in vitro hematopoiesis and is
the closest laboratory equivalent to its in vivo counter-
pant. In that marrow fibmoblasts constitute the predom-
inant cell population of MSCs and appear to play a
significant role in regulation and differentiation of
hematopoietic stem cells,2933 we used the CFU-F assay
to quantitate the changes occurring on marrow fibmo-
blast progenitors after treatment with 4-HC. In con-
tnast to hematopoietic progenitors, MSCs are nela-
tively resistant to the in vitro action of 4-HC. In fact,
much higher 4-HC doses (CFU-F ID50 235 tmol/L
4-HC V CFU-Mix ID50 31 tmol/L 4-HC) are required
to abolish the formation of colonies by CFU-F as well
as the capacity of 4-HC-tneated marrow suspensions
to give rise to functional and heterogeneous stromal
layers in LTMC. Furthermore, because the 4-HC
cytotoxicity was dose dependent on CFU-F as well as
on the stnomal progenitors giving rise to LTMC adhen-
ent layers, it is possible that the CFU-F assay might
reflect, as well as the frequency of fibroblasts, the
frequency of the other components of the marrow
stromal population in the bone marrow graft. In addi-
tion to measuring the direct toxic effect of 4-HC on
MSCs, we tested the functional capacity of stromal
layers derived from 4-HC-tneated marnows by assess-
ing their capacity to support long-term hematopoiesis.
Such stnomal layers did indeed support the long-term
production of CFU-GM in a manner similar to con-
tnols, indicating that 4-HC treatment spares enough
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MSCs to be capable of giving rise to heterogeneous
stromal layers having a normal hematopoietic func-
tional activity. Hilton has recently suggested, on the
basis of studies done on human and rodent leukemia
cell lines, that the intracellular aldehyde dehydnogen-
ase (AHD) activity is directly correlated with cycbo-
phosphamide resistance.34’35 Whether human MSCs
and plunipotent hematopoietic stem cells possess high
AHD activity responsible for their 4-HC resistance
remains to be established.
Previous studies on munine experimental models
have shown a subclinical residual MSC damage after
in vivo administration of high-dose cyclophosphamide
in multiple courses (500 mg/kg x five courses).3638 On
the other hand, addition of irradiation to lower doses of
cyclophosphamide ( 1 ,500 mad + 160 mg/kg x four
courses) produced a persistent MSC damage in the
treated animals, suggesting that radiation may be the
main factor affecting the MSC function after sequen-
tial radiation and cyclophosphamide.39 In humans,
theme is good clinical evidence that very high doses of
cyclophosphamide administered alone in vivo do not
produce irreversible damage to the MSCs. In fact, a
number of patients with small-cell lung carcinoma28
and aplastic anemia have shown recovery of autologous
bone marrow function after cyclophosphamide in max-
imally tolerated doses (ie, higher doses cause fatal
cardiac necmosis).4#{176}3 Our data, in accordance with
these in vivo observations, indicate that doses of 4-HC
currently used in vitro for autologous human marrow
transplantation have a minor quantitative toxic effect
on MSCs with no significant functional damage.
The data presented in this paper and the observation
that hematopoietic reconstitution occurs after the infu-
sion of CFU-GM-depleted, 4-HC-tneated marrow
grafts, indicate that plunipotential stem cells (which
appear not to be represented by CFU-Mix) and MSCs
are resistant to 4-HC treatment up to 300 tmol/L. In
addition, the generation of LTMCs from 4-HC-
treated manrows represents an appropriate means for
examining the toxicity of this as well as other agents on
MSC populations. The regeneration of committed
stem cells in this Dexter-type LTMC system may be a
better indicator of the survival of an earlier plunipotent
hematopoietic stem cell than the recovery of hemato-
poietic colony-forming cells.
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